Taking stock of the drug industry, from the lab to the medicine chestJune 1, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Aram Boghosian for STAT STAT+ | Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts Coherus BioSciences will sell a biosimilar of Abbvie's Humira at a steep discount, and will offer it through Mark Cuban's drug company. By Ed Silverman Medicare holds firm on Alzheimer's drug coverage policy Despite pressure from Congress and advocates, CMS isn't changing its coverage plan for new Alzheimer's drugs anytime soon. By Rachel Cohrs Insurance alone didn't guarantee adherence to Ozempic, study finds Researchers found that people with higher copays were less likely to consistently take drugs like Ozempic and Jardiance. By Elaine Chen Jose Luis Magana/AP STAT+ | Republicans want to crack down on pricey health regulations, but there are major loopholes Republicans are selling a provision of the debt ceiling deal as a way to limit health agencies' power to spend. But it has major loopholes. By Rachel Cohrs Listen: Fake medical devices, real cancer drugs, & curious Ozempic effects This episode, STAT's Lizzy Lawrence joins us to explain the shocking story of a medical device company that sold fake implants. By Damian Garde and Meg Tirrell and Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments